Panacea Biotec said it has secured permission to conduct Phase I/II trials for its live attenuated tetravalent dengue vaccine in India, and the product could be available there as of the end of 2019, reported livemint.com.
A company spokesperson said Panacea Biotec will start clinical trials by early 2018.
"As dengue is a big challenge for India and a vaccine is direly required, we have given a go-ahead for trials for dengue vaccine by TDB [Technology Development Board] and Panacea Biotec," stated G.N. Singh of the Drug Controller General of India (DCGI).
"We are facilitating the trials in a speedy manner. As a regulator, we are ensuring that the vaccine is effective and safe for the people," Singh added.
The experimental vaccine is a single-dose injection and has been found to stimulate a strong immune response against all four types of dengue viruses in all age groups, according to results from clinical trials conducted by the US National Institutes of Health.
To read more NewsPoints articles, click here.